PTO/SB/08a (07-08)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE as a politection of information unless it contains a valid OMB control number.

***************************************	***************************************			Complete if Known		
Substitute fe	or form 1449	orn		Application Number	09/990,909	
INFORM	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	November 16, 2001		
			First Named Inventor	Joan M. Fallon		
(Use as	(Use as many sheets as necessary)			Art Unit	1645	
			·	Examiner Name	Albert Mark Navarro	
Sheet	1	σĚ	7	Attorney Docket Number	41012-705.201	

		U.S. PA	TENT DOC	UMENIS	
Examines Initials*	Cite No.	Discussed Number Number-Kind Code <sup>†</sup> (if known)	Publication Date MM-DIPYYYY	Name of Patenties or Applicant of Cited Decument	Pages, Columna, Lines, Where Relevant Fasaages or Relevasit Figures Appear
	1;	US 5,439,935	08/08/1995	Rawlings of al.	
	2.	US 5,476,661	12/19/1995	Pillai et al.	
	3.	US 5,776,917	07/07/1998	Blank et al.	

		FOREIGN	PATENT DO	CUMENTS		
Exsuminer Initials*	Cite No.	Foreign Patent Document  County Code' - Number - Kled Cude' (1/ knows)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	. Pages, Columns, Lines. Where Relevant Passages On Relevant Figures Appear	34
	4.	None.		7		

Continued on the next page with more references.

the state of the s	Second Control of	
Examiner	Date	***************************************
Signsture	Commidenced	· ·
Const.W	#**COOKSESSESSESSESSES	· ·

If you need assistance in completing the form, call 1-800-9775-9199 (1-800-786-9199) and select option 2.

Attorney Docket No. 41012-705.201

\* } š

4399755\_LDOCX

EXAMPLES: Initial if reference possidered, whether or not classion is in nonformance with higher bids. Describe through shadon if not in conformance and but considered, budside posty of this form with cost consequences in a speciment. Applicant's unique classion designation empire (optional). See Kinds Codes of USFTO Facon Decrements of SON\_ASSES, pay or MFCF 901.04. You can be a finished for the form the second the decrement, by the two determined (WIFO Standard ST.)), For hypercase patent decrement, the indication of the year of the recipient of the facon of the patent of the paten

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file facel by the USPTO to proceed a application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 loves to complete, including gathering, proposing, and solutioning the completed application from to the USPTO. Time will very depending upon the individual teat. Any comments on the amount of finer year require to complete this first under augustions for reducing this fortion, should be sent to the USPTO. Time will very depending upon the individual teat. Any comments on the amount of finer year require to complete this first under augustions for reducing this fortion. Advantable, VA 22313-1450, DO NOT SEND FREE OR COMPLETED PURSON TO THIS ADDRESS. SENS TO: Commissioner for Parents, F.O. Son 1888, Alexandria, VA 22313-1450. DO NOT SEND FREE OR COMPLETED

PTO/SB/985 (97-99)

Approved for use through 07/31/2012, OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		Cor	nplete if Known
Substitute fi	or form 1449.	/PTO		Application Number	09/990,909
INFORM	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	November 16, 2001	
			First Named Inventor	Joan M. Fallon	
(Use as	(Use as many sheets as necessary)			Art Unit	1645
				Examiner Name	Albert Mark Navarro
Sheet	2	of	7.	Attorney Docket Number	41012-705.201

		NON PATENT LITERATURE DOCUMENTS	*****
lixsminer Initials*	Cite No.	include name of the author (in CAPITAL LETTERS), title of the srticle (when appropriate), title of the item (book, magazine, journal, serial, symposium, estalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Ţ
	5.	ANG, et al. Biological role and regulation of the universally conserved heat shock proteins. I Biol Chem. 1991 Dec 25;266(36):24233-6.	
	6.	ARRIBAS, et al. A comparative study of the chymotrypsin-like activity of the rat liver multicatalytic proteinase and the ClpP from Escherichia coli. J Biol Chem. 1993 Oct 5;268(28):21165-71.	
	7,	ARRIGO, et al. Expression of heat shock proteins during development in Drosophila.  Results Probl Cell Differ. 1991;17:106-19.	
	8.	AUSTIC. Development and adaptation of protein digestion. I Nutr. 1985 May;115(5):686-97.	
:	9.	AWAZUHARA, et al. Antigenicity of the proteins in soy lecithin and soy oil in soybean allergy. Clin Exp Allergy. 1998 Dec;28(12):1559-64.	
	10.	BEILMANN, et al. Neoexpression of the c-met/hepatocyte growth factor-scatter factor receptor gene in activated monocytes. Blood. 1997 Dec 1;90(11):4450-8.	
	11.	BOROWITZ, et al. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee. J Pediatr. 1995 Nov;127(5):681-4.	
	12.	BOYD, et al. Positively charged amino acid residues can act as topogenic determinants in membrane proteins. Proc Natl Acad Sci U S A. 1989 Dec;86(23):9446-50.	********
	13.	BRUHAT, et al. Amino acid limitation induces expression of CHOP, a CCAAT/enhancer binding protein-related gene, at both transcriptional and post-transcriptional levels. J Biol Chem. 1997 Jul 11;272(28):17588-93.	-
	14.	CARROCCIO, et al. Secondary impairment of pancreatic function as a cause of severe malabsorption in intestinal giardiasis: a case report. Am J Trop Med Hyg. 1997 Jun; 56(6):599-602.	-
	15.	CARROCCIO, et al. Secretin-cerulein test and fecal chymotrypsin concentration in	

Examiner	i Date	1
	1 7 7 1 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3	
Simmone	Cancidored	
THE STREET	( Committee of the comm	

If you need autistines in completing the form, call 1-860-970, 9199 (1-800-788-9199) and seince aprior 2.

Attorney Docket No. 41012-705.201

4399755\_LDOCX

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or nor charion is in conformance with MPEP 50%. Draw line through charlon if not in conformance and not considered. Include copy

of this firm with next communication to applicant.
"Applicant's unique citation designation number (applicant). "Applicant is to place a checkmark here if English language Translation is anamed.

Applicates a simple classical configuration and process (application). Application is a possest of the configuration of the configuration is required by 19 CFR, 198. The information is required to obtain or rectain a baseful by the public which is to file (and by the USPTG to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 U.S.R. 1.14. This collection is estimated to take 2 leaves to complete, including gendering, presenting, and administing the completed application forms to the USPTG. This will very depositioning upon the individual trans. Any consensate of the prior requires to complete this firms and/or taggerities for the should be sent to the Chief Information Officer, U.S. Frient and Trademark Office, F.O. Rev. 1459, Alexanderia, VA 22313-1450. DO NOT SENIO FISSS OR COMPLITIES SORAND TO:

ADDRESS, SENIO TO: Commissioner for Publish, F.O. Rev. 1450, Alexanderia, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Sinder the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

		········	***************************************		nplete if Known
Substitute to	or form 1449.	PTO.		Application Number	09/990,909
INFORM	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	November 16, 2001	
			First Named Inventor	Joan M. Fallon	
(Use as			Art Unit	1645	
	(can as waste among an instantial N			Examiner Name	Albert Mark Navarro
Sheet	3	of	7	Attorney Docket Number	41012-705.201

		NON PATENT LITERATURE DOCUMENTS	******
Examiner initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, estalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1
		children with intestinal giardiasis. Int J Pancreatol. 1993 Oct;14(2):175-80.	
************	16.	CASSIDY, et al. A new concept for the mechanism of action of chymotrypsin: the role of the low-barrier hydrogen bond. Biochemistry, 1997 Apr 15;36(15):4576-84.	
	17.	CHEN, et al. Identification of two lysosomal membrane glycoproteins. I Cell Biol. 1985 Jul;101(1):85-95.	
	18.	CORRING, et al. Development of digestive enzymes in the piglet from birth to 8 weeks. I. Pancreas and pancreatic enzymes. Nutr Metab. 1978;22(4):231-43.	
	19.	COUET, et al. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J Biol Chem. 1997 Mar 7;272(10):6525-33.	
	20.	CRAIG, et al. Heat shock proteins: molecular chaperones of protein biogenesis. Microbiol Rev. 1993 Jun;57(2):402-14.	
	21.	CROONENBERGHS, et al. Peripheral markers of serotonergic and noradrenergic function in post-pubertal, caucasian males with autistic disorder. Neuropsychopharmacology. 2000 Mar;22(3):275-83.	
	22.	EDELSON, et al. 3-Cyclohexene-1-glycine, an Isoleucine Antagonist. J. Am. Chem. Soc. 1958; 80(11):2698-2700.	
	23.	ETHRIDGE, et al. Acute pancreatitis results in induction of heat shock proteins 70 and 27 and heat shock factor-1. Pancreas. 2000 Oct;21(3):248-56.	
	24.	FAFOURNOUX, et al. Amino acid regulation of gene expression. Biochem J. 2000 Oct 1;351(Pt 1):1-12.	
	25.	FALLINGBORG, et al. Measurement of gastrointestinal pH and regional transit times in normal children.  J Pediatr Gastroenterol Nutr. 1990 Aug; 11(2):211-4.	
	26.	FITZSIMMONS, et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med. 1997 May 1;336(18):1283-	******

	***************************************	****	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
examiner :		Date	\$
	· .	cours.	\$
Secretarios		Commentation of	· ·
wigname.	}	N. ODSKICKSSKI	)

If you need assistance to completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Attorney Docket No. 41012-705.201

<sup>\*</sup>EXAMINER: Initial if informace considered, whether or an charico is in conformance with MFRF 600. Down line through charine if nor in conformance and not considered. Include copy

<sup>\*</sup>EXAMINER: Initial if inference considered, whether or not classics is in conformance with MFEP bits. Drew jute through citation is no incommence and not concentrate. Incline copy of this form with next communication to applicate.

\*Applican's unique classics designation number (options). \*Applicant is to place a checkmark here if English integrage Translation is attached.

This collection of information is required by 37 CFR 1.58. The information is required to class a benefit by the public which is to file (and by the HSFFO in process) as application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is enforced to take 2 hours to complete, including gathering, preparing, and substituting the commence application. In the USFFO. Thus will vary depending upon the individual case. Any commence on the price which to complete this form notifier suggestions for receiving this bonder, should be sent to the Chief Information Officer, U.S. Pates and Tenderous' Officer, P.O. Box 1450, Alexandria, VA 22313-1480. DE BOT SEND FEES OR COMPLETED BORMS TO THIS ADDRESS. SEND TO: Commissioner for Fatests, P.O. Box 1450, Alexandria, VA 21313-1499; and select notion 2.

Approved for use through 07/31/2012. OMS 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Linder the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

	***************************************	,		Complete if Known		
Substitute fo	or form 1449	/PTO		Application Number	09/990,909	
INFORM	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	November 16, 2001		
STATEN			First Named Inventor	Joan M. Fallon		
(Use as			Art Unit	1645		
				Examiner Name	Albert Mark Navarro	
Sheet	4	of	7	Attorney Docket Number	41012-705.201	

Cits No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  9.  GARDNER. Absorption of infact peptides: studies on transport of protein digests and	**
27.		ļ
27.	GARDNER. Absorption of intact peptides: studies on transport of protein digests and	£
	dipeptides across rat small intestine in vitro, Q J Exp Physiol. 1982 Oct;67(4):629-37.	***************************************
28.	GARNER Jr, et al. Porcine Pancreatic Lipase - A Glycoprotein. J Biol Chem. 1972 Jan 25;247(2):561-5.	
29.	GIGLIO, et al. Failure to thrive: the earliest feature of cystic fibrosis in infants diagnosed by neonatal screening. Acta Paedistr. 1997 Nov;86(11):1162-5.	
30.	GOFF, et al. Production of abnormal proteins in E. coli stimulates transcription of lon and other heat shock genes. Cell. 1985 Jun;41(2):587-95.	
31.	GREEN, et al. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 1994 Aug 16;33(32):9414-9.	
32.	GUPTA, et al. Th1- and Th2-like cytokines in CD4+ and CD8+ T cells in autism. J Neuroimmunol. 1998 May 1;85(1):106-9.	
33,	HADIIVASSILIOU, et al. Does cryptic gluten sensitivity play a part in neurological illness? Lancet. 1996 Feb 10;347(8998):369-71.	
34.	HORVATH, et al. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr. 1999 Nov;135(5):559-63.	
35.	HUANG, et al. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases. Hum Mol Genet. 1997 Oct;6(11):1879-85.	
36.	HUANG, et al. Mapping of the human APOB gene to chromosome 2p and demonstration of a two-allele restriction fragment length polymorphism. Proc Natl Acad Sci U S A. 1986 Feb;83(3):644-8.	
37.	JUHL, Fibromyalgia and the serotonin pathway. Altern Med Rev. 1998; 3(5):367-375.	
38.		
**************		
	(9), (1), (3), (4), (5),	J Biol Chem. 1972 Jan 25;247(2):561-5.  GIGLIO, et al. Failure to thrive: the earliest feature of cystic fibrosis in infants diagnosed by neonatal screening. Acta Paediatr. 1997 Nov;86(11):1162-5.  GOFF, et al. Production of abnormal proteins in E. coli stimulates transcription of lon and other heat shock genes. Cell. 1985 Jun;41(2):587-95.  GREEN, et al. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 1994 Aug 16;33(32):9414-9.  GUPTA, et al. Th1- and Th2-like cytokines in CD4+ and CD8+ T cells in autism. J Neuroimmunol. 1998 May 1;85(1):106-9.  HADJIVASSILIOU, et al. Does cryptic gluten sensitivity play a part in neurological illness? Lancet. 1996 Feb 10;347(8998):369-71.  HORVATH, et al. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr. 1999 Nov;135(5):559-63.  HUANG, et al. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases. Hum Mol Genet. 1997 Oct;6(11):1879-85.  HUANG, et al. Mapping of the human APOB gene to chromosome 2p and demonstration of a two-allele restriction fragment length polymorphism. Proc Natl Acad Sci U S A. 1986 Feb;83(3):644-8.  JUHL. Fibromyalgia and the serotonin pathway. Altern Med Rev. 1998; 3(5):367-375.

Signsture

\*Considered

\*EXAMINER: Initial if reference considered, obether or not citation is in conformance with NOVEP \$09. Draw fine through elation if not be conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique custion designation number (optional). Applicant is to place a checkmank here if linglish language Translation is anached.

Applicant a longing resource configuration storage represents. Application is a sequence to the complete suggest transacting in required to the CERTO in process) an application. Dissipation of information is required by 31 CERTO 114. This collection is activated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form in the UNITO. Time will vary depending upon the individual case. Any comments on the associated from your requires to complete this form analizer suggestions for reducing this hundred, should be sent to the CREAT Information of Processors for Processors of the plant of these your requires to complete this form analizer suggestions for reducing this hundred, should be sent to the CREAT Information Officer, U.B. Process and Transactions (Prince, P.O. Box 1456), Associate, VA 22313-1456. DOI NOT SENO FEIRS OR COMPLETED PUBLIS TO THE ARRESTS. SENO TO: Commissioner for Processor Processors of the CREAT INFORMATION OF THE ARRESTS.

If you need arrivance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Attorney Docket No. 41012-705.201

4399755\_LDOCX

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademerk Office; U.S. DEPARTMENT OF COMMERCE. of information union it contains a write OME custom mittable

	Under the Paperwork Reduction Act of 1995, no persons				Complete if Known		
Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/990,909		
			LOSURE	Filing Date	November 16, 2001		
				Pirst Named Inventor	Joan M. Fallon		
				Art Unit	1645		
		Examiner Name	Albert Mark Navarro				
Sheet	5	of	7	Attorney Docket Number	41012-705.201		

		NON PATENT LITERATURE DOCUMENTS	·
Examiner Initials*	e* No.' publisher, city and/or country where published.		43
		12(2):98-105.	
	39,	LLOYD, Lysosome membrane permeability: implications for drug delivery. Adv Drug Deliv Rev. 2000 Mar 30;41(2):189-200.	
	40.	LUEDTKE, et al. Cathepsin A is expressed in a cell- and region-specific manner in the testis and epididymis and is not regulated by testicular or pituitary factors. J Histochem Cytochem, 2000 Aug;48(8):1131-46.	
	41,	MANNINO, et al. Surveillance for asthmaUnited States, 1960-1995. MMWR CDC Surveill Summ. 1998 Apr 24;47(1):1-27.	
	42.	MCCORMACK, et al. Localization of the disulfide bond involved in post-translational processing of glycosylasparaginase and disrupted by a mutation in the Finnish-type aspartylglycosaminuria. J Biol Chem. 1995 Feb 17;270(7):3212-5.	
	43.	MELMED, et al. Metabolic markers and gastrointestinal symptoms in children with autism and related disorders. J Pediatr Gast Nutr. 2000; 31:S31-S32.	***************************************
	44,	MONONEN, et al. Aspartylglycosaminuria in the Finnish population: identification of two point mutations in the heavy chain of glycoasparaginase. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2941-5.	
	45.	NEUER, et al. The role of heat shock proteins in reproduction. Hum Reprod Update. 2000 Mar-Apr;6(2):149-59.	
	46.	Office Action dated 05/24/11 for US Application 12/487,864,	
	47,	PURI, ot al. Isolated segmental duodenal ganglionosis. Indian Journal of Radiology and Imaging, 2000; 153-154.	
***************************************	48.	RIDER, et al. Perspective of biochemical research in the neuronal ceroid-lipofuscinosis. Am J Med Genet. 1992 Feb 15;42(4):519-24.	
	49.	ROTTIER, et al. Lack of PPCA expression only partially coincides with lysosomal storage in galactosialidosis mice: indirect evidence for spatial requirement of the catalytic rather than the protective function of PPCA. Hum Mol Genet, 1998	

Secretary of the second	himmen and a second			***************************************	<del>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</del>	<del>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</del>
E PEXACONOMIC	i			Division	•	
are a construction of	i		4	LODGE .	₹	
₹ - 855 xxxx xxx xxx xxx x x x x x x x x x	3		!		<b>}</b>	
{ organiums	1		į	Considered	8	
Assessed the same of the same	***************************************	*******************************		ACCOMMODISTING		

<sup>[</sup>ASSISTED]

\*\*EXAMINER: Initial II reference containing, whether at mel citation is in conformance with MPIP 809. Draw line through citation if no to conformance and not considered, include copy of this form with next communication to applicant.

\*Applicant's unique citation dealgastion number (optional). \*Applicant to in place a checkmark here if English language Translation is attached.

This collection of information is required by 31 CFS 1.88. The information is required in obtain or retain a linearity by the public which is to file (seed by the USPTO to governed) as application. Confidentially is governed by 35 U.S. C. 122 and 17 CFS 1.18. This collection is confident to take 1 hours to inducting childring gathering, properting, and attentioning the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete the form and/or suggestions for reducing this horizon and/or suggestions for reducing this particular that the Chief Information Officer, U.S. Fracm and Trademark Office, P.O. But 1436, Alexandria, VA 12313-1450. DO NOT SEND PRICE OR COMPLETED PUBLIS TO THIS ADDRESS. SEND PO: Commissioner for Patents, P.O. But 3430, Alexandria, VA 12313-1450.

[Journal of Commissioner for Patents, P.O. But 1436, Alexandria, VA 12313-1450.]

PTO/SB/085 (07-09)

Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number

				Complete if Known		
Substitute for form 1449/PTO INFORMATION DISCLOSURE				Application Number	09/990,909	
				Filing Date	November 16, 2001	
STATE	STATEMENT BY APPLICANT			First Named Inventor	Joan M. Fallon	
(Use as many sheets as necessary)			cessary)	Art Unit	1645	
		Examiner Name	Albert Mark Navarro			
Sheet	6	of	7	Attorney Docket Number	41012-705.201	

,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	· · · · · · · · · · · · · · · · · · ·	NON PATENT LITERATURE DOCUMENTS	·
Examiner Initials*	Cire No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		Oct;7(11):1787-94.	
	50.	SABRA, et al. Linkage of ileal-lymphoid-nodular hyperplasia (ILNH), food allergy and CNS developmental: evidence for a non-IgB association. Ann Aller Asth Immunol. 1999; 82:8.	
	51.	SANDLER, et al. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med. 1999 Dec 9;341(24):1801-6.	
	52.	SCHAFER, et al. Stress kinuses and heat shock proteins in the pancreas: possible roles in normal function and disease. J Gastroenterol. 2000;35(1):1-9.	
	53,	SINGH, et al. Plasma increase of interleukin-12 and interferon-gamma. Pathological significance in autism. J Neuroimmunol. 1996 May;66(1-2):143-5.	
	54.	STEIN, et al. Nitrogen metabolism in normal and hyperkinetic boys. Am J Clin Nutr. 1984 Apr;39(4):520-4.	
	55,	STEINHERZ, et al. Patterns of amino acid efflux from isolated normal and cystinotic burnan leucocyte lysosomes. J Biol Chem. 1982 Jun 10;257(11):6041-9.	
	56.	STOLL, et al. Enteral nutrient intake level determines intestinal protein synthesis and accretion rates in neonatal pigs. Am J Physiol Gastrointest Liver Physiol. 2000 Aug;279(2):G288-94.	
	57.	STRADER, et al. Publication Structural basis of B-adrenergic receptor function. FASEB J. 1989 May;3(7):1825-32.	
***************************************	58.	THOMAS, et al. Defective protein folding as a basis of human disease. Trends Biochem Sci. 1995 Nov;20(11):456-9.	
	59,	VILANOVA, et al. Preparative isolation of the two forms of pig pancreatic pro- (carboxypeptidase A) and their monomeric carboxypeptidases A. Biochem J. 1985 Aug 1;229(3):603-9.	
	60.	VOLKMAR, et al. Practice parameters for the assessment and treatment of children,	1

Examiner	Date	***************************************	
Simonwa	Considered		

Hypu need assistance in completing the form, call 1-800-PTO-9190 (1-800-186-9199) and solaci uption 2.

<sup>|</sup> Signature | Constituted |
\*EXAMINE: Indical if reference considered, whether or put chapton is in conformance with MPEP 609. Draw line through chapton if not in conformance and not considered. Include uspy
et also from with next communication to application.
\*Applicant's unique chance designation number (optional). \*Applicant is to place a checkmark here if English language Translation is structed.
This collection of information is required by 37 CFR 1/8. The information is required to obtain or resion a benefit by the public which is to file (and by the USPTO to process) an application.
Confidentiality is governed by 37 U.S.C. (22 and 37 CFR 1/8. The information is estimated in take 2 hours to complete, including gathering, proparing, and submitting the completed application
form to the USPTO. Time will vary depending upon the individual case. Any information in the anatom of time you require to complete this firm suchre suggestions for reducing this burden,
should be sent to the Chief Information Offices, U.S. Parcel and Trademark Offices, F.C. Box 1450. Alexandria, VA 22313-1450. DO NOT SEND FEED OR COMPLITED FORMS TO THOS
address. SKNR TO: Commissioner for Patentia, R.O. Bux 1450, Alexandria, VA 22313-1459.

If you need assistances in completing the form, cell I-800-PTO-9199 (I-800-PTO-9199) and select apoles 2.

Approved for use through 07/31/2012. OM8 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	,			Complete if Known	
Substitute fo	Substitute for form 1449/PTO			Application Number	09/990,909
INFORM	IATION I	DISC	LOSURE	Filing Date	November 16, 2001
1	STATEMENT BY APPLICANT (Use as many sheets as necessary)			First Named Inventor	Joan M. Fallon
(Use as				Art Unit	1645
				Examiner Name	Albert Mark Navarro
Sheet	7	οf	7	Attorney Docket Number	41012-705.201

	;·····	NON PATENT LITERATURE DOCUMENTS   Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	7
Examiner initisis*	Cite No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	J.
	***************************************	adolescents, and adults with autism and other pervasive developmental disorders.  American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. J Am Acad Child Adolesc Psychiatry. (PART 1) 1999 Dec;38(12 Suppl):32S- 54S.	
	61.	VOLKMAR, et al. Practice Parameters for the Assessment and Treatment of Children, Adolescents, and Adults with Autism and other Pervasive Developmental Disorders.  American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. (PART 2) 1999 Dec;38(12):1611-6.	
	62.	WAKEFIELD, et al. Enterocolitis in children with developmental disorders. Am J Gastroenterol. 2000 Sep;95(9):2285-95.	
	63.	WAKEFIELD, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998 Feb 28;351(9103):637-41.	
	64.	WALSH, et al. Heat shock and the role of the HSPs during neural plate induction in early mammalian CNS and brain development. Cell Mol Life Sci. 1997 Feb;53(2):198-211.	,
	65.	WEINTRAUB, et al. Morphometric studies of pancreatic acinar granule formation in NCTR-Balb/c mice. J Cell Sci. 1992 May;102 ( Pt 1):141-7.	
***************************************	66.	WILLIAMS, et al. Eating habits of children with autism. Pediatr Nurs. 2000 May- Jun;26(3):259-64.	
	67.	YOUNGBERG, et al. Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects. Dig Dis Sci. 1987 May;32(5):472-80.	
	68.	YUAN, et al., Preeze-Thaw Stability of Three Waxy Maize Starch Pastes Measured by Centrifugation and Calorimetry, Cereal Chem, 1998; 75(4):571-573,	
	69.	ZEINER, et al. Mammalian protein RAP46: an interaction partner and modulator of 70 kDa heat shock proteins. EMBO J. 1997 Sep 15;16(18):5483-90.	***************************************

P	
Examiner	Diese
(Albert M Navarro)	1
Signature	Considered OULIZOII
The state of the s	( 2000)0000

<sup>\*</sup>EXAMINEM: Initial if reference considered, whether it and citation is in conformance with MPEP 609. Data line through checien if not in conformance and not considered. Include copy

<sup>\*\*</sup>EAMINENT Total if reference countered, whether it not citation is in conformance with MPEP 609. Draw line through chains if not is conformance and not considered. Include copy of this form with next communication to applicate.

\*Applican's unique citation designation number (optional). \*Applican as a checkmark here if English language Translation is attached.

The collection of information is required by 37 DPR 1.98. The information is required to obtain or main a heretic by the public which is to file (and by the USPTO to governs) as application. Confidentially, is governed by 35 U.S.C. 122 and 37 DPR 1.14. This collection is entired to take 2 hours no complete, including gathering, propering, and intentiting the completed application from vall year depending upon the individual case. Any convents on the amount of time you require to complete the importance of the confidence of the property of the public with the sent to the Closel information Officer, U.S. Parent and Tradmark Office, P.O. But 1459, Alexandria, VA 22313-1456. DO NOT SEND FIELS OR COMPLETED PORMS TO THIS ADDRESS. SIND TO: Commissioner for Patents, F.O. But 1439, Alexandria, VA 22313-1456.

If you need accitance to complicing the form, cell 1.409-PTO-9199 (1.800-786-9199) and select applican 2.